Journal article
A1C for Screening and Diagnosis of Type 2 Diabetes in Routine Clinical Practice
Zhong X Lu, Karen Z Walker, Kerin O'Dea, Ken A Sikaris, Jonathan E Shaw
DIABETES CARE | AMER DIABETES ASSOC | Published : 2010
DOI: 10.2337/dc09-1763
Abstract
OBJECTIVE: To evaluate A1C for screening and diagnosis of undiagnosed type 2 diabetes defined by oral glucose tolerance testing in clinical and general populations. RESEARCH DESIGN AND METHODS: A1C cut offs ( or =7.0% to rule in diabetes) were derived from a clinical group (Melbourne Pathology [MP] group: n = 2,494; undiagnosed diabetes 34.6%) and then evaluated in a population-based sample (AusDiab group: n = 6,015; undiagnosed diabetes 4.6%). RESULTS: For diabetes in the MP and AusDiab groups, A1C at 5.5% gave sensitivities of 98.7 and 83.5%, while A1C at 7.0% gave specificities of 98.2 and 100%, respectively. Many (61.9-69.3%) with impaired A1C (5.6-6.9%) in both populations had abnormal ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
The AusDiab study, co-coordinated by the Baker IDI Heart and Diabetes Institute, gratefully acknowledges the generous support given by the National Health and Medical Research Council (Grant no. 233200); the Australian Government Department of Health and Ageing; Abbott Australasia; Alphapharm; AstraZeneca; Bristol-Myers-Squibb; City Health Centre, Diabetes Service, Canberra; the Department of Health and Comm unity Services, Northern Territory; the Department of Health and Human Services, Tasmania; the Department of Health, New South Wales; the Department of Health, Western Australia; the Department of Health, South Australia; the Department of Human Services, Victoria; Diabetes Australia; Diabetes Australia Northern Territory; Eli Lilly Australia; the estate of the late Edward Wilson; GlaxoSmithKline; the Jack Brockhoff Foundation; Janssen-Cilag; Kidney Health Australia; the Marian & FH Flack Trust; the Menzies Research Institute; Merck Sharp & Dohme; Novartis Pharmaceuticals; Novo Nordisk Pharmaceuticals; Pfizer; the Pratt Foundation; Queensland Health; Roche Diagnostics Australia; Royal Prince Alfred Hospital, Sydney; Sanofi-Aventis; and Sanofi Synthelabo.